BTG plc’s (BTG) Hold Rating Reaffirmed at Stifel Nicolaus
BTG plc (LON:BTG)‘s stock had its “hold” rating reaffirmed by Stifel Nicolaus in a research note issued to investors on Thursday. They currently have a GBX 640 ($8.35) target price on the stock. Stifel Nicolaus’ target price would indicate a potential downside of 1.08% from the stock’s current price.
BTG has been the topic of a number of other research reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of BTG plc in a research note on Friday, September 9th. Numis Securities Ltd restated a “hold” rating and set a GBX 737 ($9.62) target price on shares of BTG plc in a research note on Thursday, July 14th. Jefferies Group raised their target price on shares of BTG plc from GBX 840 ($10.96) to GBX 860 ($11.23) and gave the stock a “buy” rating in a research note on Wednesday, June 29th. Deutsche Bank AG restated a “buy” rating and set a GBX 740 ($9.66) target price on shares of BTG plc in a research note on Wednesday, June 15th. Finally, Royal Bank Of Canada raised their target price on shares of BTG plc from GBX 820 ($10.70) to GBX 890 ($11.62) and gave the stock an “outperform” rating in a research note on Wednesday, June 8th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of GBX 793.86 ($10.36).
BTG plc (LON:BTG) opened at 680.50 on Thursday. The company’s 50-day moving average is GBX 626.72 and its 200-day moving average is GBX 640.49. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 739.50. The company’s market cap is GBX 2.61 billion.
In related news, insider Soderstrom,Rolf sold 74,327 shares of the firm’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of GBX 676 ($8.82), for a total value of £502,450.52 ($655,855.01).
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.